Victoria L. Campion

Is initial treatment with dasatinib for newly diagnosed chronic Phase chronic myeloid leukemia, followed by switching to imatinib for those that achieve MR3.0 at 12 months, an effective strategy? Results of the Phase 2 kinase inhibition with sprycel startup study

Peter Browett, Zhenqiang Wu, Humphrey W. H. Pullon, Jenny Yoon et autres

Abstract Introduction Frontline treatment of chronic phase chronic myeloid leukemia (CP-CML) with the second-generation tyrosine kinase inhibitors (2G-TKI) results in a more rapid and deeper molecular response than with imatinib (IM), but is associated with an increased risk of significant long term …

nz (code pays fourni par la source)

Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial

Lise J Estcourt, Zoe McQuilten, Peter Bardy, Merrole Faye Cole-Sinclair et autres

ANZTCT practice statement: sinusoidal obstruction syndrome/veno‐occlusive disease diagnosis and management

Shaun A. Fleming, Ashleigh P. Scott, John Coutsouvelis, Chris Fraser et autres

Sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) is a life-threatening complication which can develop after haemopoietic stem cell transplantation (HSCT) and some antibody-drug conjugates. Several SOS/VOD diagnostic and management guidelines exist, with the most recent and refined being the European Society for Blood and …

au, nz (code pays fourni par la source)

P675: IMATINIB THERAPY IN PREVIOUSLY UNTREATED CHRONIC MYELOID LEUKAEMIA PATIENTS WHO ACHIEVE MMR AFTER 12 MONTHS THERAPY WITH DASATINIB: A STRATEGY TO AVOID LONG TERM OFF TARGET TOXICITY

Lucy C. Pemberton, Katrina J. SHARPLES, Yujin Kim, Emma-Jane Mcdonald et autres

Background: Despite the impressive outcomes seen with tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukaemia (CML), the optimal upfront therapy remains unclear. Second generation TKI (2G TKI) trials have shown significantly more rapid and deeper levels of molecular response with a …

nz (code pays fourni par la source)

Acute myeloid leukaemia with NPM1 mutation: no longer having an absolute blast (count)

Lucy Zhang, Victoria L. Campion, Michelle Dickson, Catherine Tang

au, nz (code pays fourni par la source)

A randomized controlled feasibility trial of paracetamol during febrile neutropenia in hemato-oncology patients

Robert Weinkove, Emily R Bowden, Catherine Wood, Victoria L. Campion et autres

The efficacy of paracetamol (acetaminophen) as an antipyretic during febrile neutropenia (FN) has not previously been established. We conducted a randomized double-blind placebo-controlled feasibility trial: hemato-oncology patients at high FN risk were randomly assigned to six hourly oral paracetamol (1 g) or …

nz (code pays fourni par la source)

Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma

Ju Dong Yang, Michael B. Campion, Minetta C. Liu, Roongruedee Chaiteerakij et autres

UNLABELLED: Circulating tumor cells (CTCs) in blood are associated with poor survival of patients with breast, prostate, or colon cancer. We hypothesized that CTCs are associated with poor survival of patients with cholangiocarcinoma (CCA). Eighty-eight patients with CCA were prospectively enrolled at …

us, th (code pays fourni par la source)

584 Circulating Tumor Cells Are Associated With Poor Overall Survival in Patients With Cholangiocarcinoma

Ju Dong Yang, Michael B. Campion, Roongruedee Chaiteerakij, Nasra H. Giama et autres

Circulating Tumor Cells in Cholangiocarcinoma

Ju Dong Yang, Michael B. Campion, Roongruedee Chaiteerakij, Teresa A. Mettler et autres

Two Decades of Hepatocellular Carcinoma: Characteristics in 1,170 Patients

Ju Dong Yang, Michael B. Campion, Roongruedee Chaiteerakij, Teresa A. Mettler et autres

present more frequently after TARE sessions (10 (35%) vs 7 (10%), P=0.008) and 27 (93%) vs 48 (71%), respectively, P=0.03). Conclusions: TARE resulted in similar survival and overall tumor responses to TACE in treatment of unresectable ICC. Nodules treated with TAREwere more …